Brought to you by 
Actavis, Watson divest products and candidates to Par to satisfy merger conditions
18 Nov 2022
Executive Summary
To satisfy FTC conditions associated with Watson Pharmaceuticals Inc.’s $5.6bn purchase of privately held generics firm Actavis Group, the two companies have agreed to divest a total of 14 generics (marketed products, pending ANDAs, and a development project) to Par Pharmaceutical Cos. Inc., which paid an undisclosed sum in cash.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Actavis, Watson divest products and candidates to Par to satisfy merger conditions
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice